Hepatitis

PubMed Free Full Text

Hepatitis C

• Revista Española de Sanidad Penitenciaria
  • Using time in prison as an ideal opportunity to treat Hepatitis C - PIONEER Framework Proposal [2025]

Albania

• Virology Journal
  • Treatment and follow up of children with chronic hepatitis C in Albania [2012]

Asia

• Asian Pacific Association for the Study of the Liver
  • Toward the hepatitis C virus elimination in Asia: The policy forum from the 2023 Asian Pacific Association of the Study of the Liver (APASL) [2023]

• International Liver Transplantation Society
  • International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation [2019]

• KDIGO
  • 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report [2020]

• Korean Journal of Internal Medicine
  • A 2015 roadmap for the management of hepatitis C virus infections in Asia [2015]

Asia-Pacific

• Asian Pacific Association for the Study of the Liver
  • APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? [2019]
  • APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation [2019]
  • APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing [2016]
  • APASL consensus statements and recommendation on treatment of hepatitis C [2016]

• Journal of Virus Eradication
  • The hepatitis C treatment revolution: how to avoid Asia missing out [2015]

• Pathogens
  • Hepatitis C in Children-An Asia-Pacific Concise Perspective [2024]

Australia

• Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine
  • HCV in Children: Australian Commentary on AASLD-IDSA Guidance [2021]
  • National HCV Testing Policy
  • Hepatitis C

• Australian Family Physician
  • A practical overview of the treatment of chronic hepatitis C virus infection [2016]
  • Hepatitis C – an update [2013]

• Australian Journal of General Practice
  • Hepatitis C direct-acting antiviral treatment completion: Comparison of geographic, demographic and clinical characteristics in Australia [2023]
  • Treating chronic hepatitis C in general practice [2021]
  • Insights into the management of chronic hepatitis C [2018]

• Australian Prescriber
  • Treating hepatitis C – what’s new? [2015]

• BMC Gastroenterology
  • Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up [2022]

• Clinical Infectious Diseases
  • The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia [2026]

• ClinicoEconomics and Outcomes Research
  • The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia [2017]

• Drug and Alcohol Review
  • Alcohol does not impact chronic hepatitis C treatment outcomes but increases risk for progressive liver disease: Findings from a prospective multicentre Australian study (OPERA-C) [2024]

• Gastroenterological Society of Australia
  • Screening and diagnosis [2022]
  • Goal of treatment of chronic hepatitis C [2022]
  • Australian recommendations for the management of hepatitis C virus infection: a consensus statement (2022) [2022]

• Hepatology Communications
  • Increasing national trend of direct-acting antiviral discontinuation among people treated for HCV 2016-2021 [2023]

• Journal of Viral Hepatitis
  • Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016-2024 [2025]

• NSW Health
  • Hepatitis C control guideline

• PLoS ONE
  • Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis [2021]

• WA Health
  • Hepatitis C

Australia, New Zealand

• Australasian Hepatology Association
  • The Australasian Hepatology Association consensus guidelines for the provision of adherence support to patients with hepatitis C on direct acting antivirals [2016]

• Royal Australian and New Zealand College of Psychiatrists
  • Treating hepatitis C [2022]

Austria

• Wiener klinische Wochenschrift
  • Integrating public health policies in the epidemiological modeling of hepatitis C with LEHC tool: application in Austria [2021]

Baltic countries, Ukraine

• Medicina
  • Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study [2023]

Brazil

• Arquivos de Gastroenterologia
  • Micro-elimination of hepatitis C in the incarcerated population: is it really possible? [2021]

• BMC Public Health
  • The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy [2016]

• Brazilian Journal of Infectious Diseases
  • National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents [2022]
  • How are HCV-infected patients being identified in Brazil: a multicenter study [2019]
  • Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil [2018]

• Ciência & Saúde Coletiva
  • Public procurement of hepatitis C medicines in Brazil from 2005 to 2015 [2017]

• Cost Effectiveness and Resource Allocation
  • Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil [2013]

• International Journal of Hepatology
  • Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective [2015]

• Revista da Sociedade Brasileira de Medicina Tropical
  • Cost-utility analysis of interferon-free treatments for patients with early-stage genotype 1 hepatitis C virus in Brazil [2020]

Cambodia

• Bulletin of the World Health Organization
  • Nurse-led initiation of hepatitis C care in rural Cambodia [2023]

Canada

• Alberta Health Services
  • Hepatitis C Virus Primary Care Pathway

• Canada's Drug Agency
  • Direct-Acting Antivirals for Pediatric Chronic Hepatitis C Virus Infection [2023]
  • Acoustic Radiation Force Impulse Imaging for Diagnosis and Monitoring of Liver Fibrosis in Patients with Hepatitis C: A Review of Diagnostic Accuracy, Clinical Effectiveness, Cost-Effectiveness, and Guidelines [2016]
  • Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence [2015]
  • Triple Therapy for Hepatitis C in Previous Non-responders: A Review of the Clinical Effectiveness and Safety [2014]
  • Treatments for Patients with Genotype 1 Chronic Hepatitis C: A Review of Evidence-based Guidelines [2014]
  • Interferon-free Regimens for Genotype 1 Chronic Hepatitis C: A Review of the Clinical Evidence and Cost-Effectiveness [2014]
  • Hepatitis C Polymorphism Testing: A Review of the Clinical Evidence [2014]

• Canadian Association for the Study of the Liver
  • The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver [2018]
  • An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver [2015]

• Canadian Family Physician
  • Primary care flow sheet for hepatitis C virus [2016]

• Canadian Journal of Gastroenterology & Hepatology
  • The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C [2016]
  • Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan [2016]
  • Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: A policy statement and implementation guideline [2014]

• Canadian Paediatric Society
  • The management of infants, children, and youth at risk for hepatitis C virus (HCV) infection [2021]

• Canadian Task Force on Preventive Health Care
  • Recommendations on hepatitis C screening for adults [2017]
  • Hepatitis C (2017) [2017]

• CanHepC - Canadian Network on Hepatitis C
  • Hepatitis C models of care: approaches to elimination [2020]
  • Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be? [2019]
  • Blueprint to Inform Hepatitis C Elimination Efforts in Canada [2019]
  • The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges? [2018]
  • Reversing immune dysfunction and liver damage after direct-acting antiviral treatment for hepatitis C [2018]
  • Remaining clinical issues in hepatitis C treatment [2018]
  • Progress toward approval of an HCV vaccine [2018]
  • Hepatitis C: A Canadian perspective [2018]
  • Can we afford not to screen and treat hepatitis C virus infection in Canada? [2018]
  • Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada [2018]
  • Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study [2016]

• Clinical Liver Disease
  • Hepatitis C Virus Prevalence, Screening, and Treatment Among People Who Are Incarcerated in Canada: Leaving No One Behind in the Direct-Acting Antiviral Era [2021]

• CMAJ
  • A Canadian screening program for hepatitis C: Is now the time? [2013]

• CMAJ Open
  • Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis [2017]
  • Systematic review of the accuracy of antibody tests used to screen asymptomatic adults for hepatitis C infection [2016]

• Government of Alberta
  • Hepatitis C screening in Alberta : a health technology assessment
  • Alberta public health disease management guidelines : Hepatitis C acute (acute case)
  • Alberta public health disease management guidelines : Hepatitis C (chronic case)

• JAMA Network Open
  • Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model [2020]

• Journal of Viral Hepatitis
  • Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis [2024]

• PLoS ONE
  • Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs? [2015]

• Public Health Agency of Canada
  • Hepatitis C: Symptoms and treatment
  • Hepatitis C virus
  • Hepatitis C treatment trends in Canada

• Public Health Ontario
  • Hepatitis C

Canada, United States

• North American Society for Pediatric Gastroenterology, Hepatology and Nutrition
  • Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper [2020]

China

• BMC Public Health
  • The macroeconomic burden of hepatitis C and the economic benefit of accelerated investments in China [2025]

• BMJ Global Health
  • Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspective [2020]

• Clinical and Molecular Hepatology
  • Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study [2025]

• Frontiers in Microbiology
  • Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives [2022]

• Frontiers in Public Health
  • Management of in- and out-of-hospital screening for hepatitis C [2023]

• Global Health & Medicine
  • Prevalence, diagnosis, and treatment of hepatitis C in Mainland China [2021]

• Infectious Diseases and Therapy
  • Eliminate Hepatitis C as a Public Health Threat: A Narrative Review of Strategies, Gaps, and Opportunities for China [2022]

• Infectious Diseases of Poverty
  • Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China? [2025]

• International Journal of Environmental Research and Public Health
  • Economic Evaluation of Hepatitis C Treatment Extension to Acute Infection and Early-Stage Fibrosis Among Patients Who Inject Drugs in Developing Countries: A Case of China [2020]

• Journal of Clinical and Translational Hepatology
  • Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China [2021]

• Journal of Clinical Gastroenterology
  • Current Challenges and the Management of Chronic Hepatitis C in Mainland China [2014]

• PLoS ONE
  • Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data [2016]

• World Journal of Gastroenterology
  • Current treatment of chronic hepatitis C in China: Dilemma and potential problems [2016]

Colombia

• Pharmacology Research & Perspectives
  • Evaluating the centralized purchasing policy for the treatment of hepatitis C: The Colombian CASE [2019]

Commonwealth of Independent States, Ukraine

• World Journal of Gastroenterology
  • Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions [2019]

Cyprus

• World Journal of Gastroenterology
  • Planning the hepatitis C virus elimination in Cyprus: A modeling study [2021]

Eastern Europe, Central Asia

• Liver International
  • Cost-Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central Asia [2025]

Egypt

• Alimentary Pharmacology & Therapeutics
  • Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies [2015]

• Global Health: Science and Practice
  • Egypt's Ambitious Strategy to Eliminate Hepatitis C Virus: A Case Study [2021]

• International Journal of General Medicine
  • Hepatitis C in Egypt – past, present, and future [2016]

• Journal of Clinical and Translational Hepatology
  • Interaction Between the Neglected Tropical Disease Human Schistosomiasis and HCV Infection in Egypt: a Puzzling Relationship [2014]

• Lancet Global Health
  • Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study [2014]

• Pathogens
  • Hepatitis C Elimination in Egypt: Story of Success [2024]

• PLoS ONE
  • Accelerating Hepatitis C virus elimination in Egypt by 2030: A national survey of communication for behavioral development as a modelling study [2021]
  • Validation of EGCRISC for Chronic Hepatitis C Infection Screening and Risk Assessment in the Egyptian Population [2016]

Europe

• BMC Infectious Diseases
  • Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries [2014]
  • A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region [2014]

• BMC Public Health
  • Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action [2020]
  • Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe [2019]

• European Association for the Study of the Liver
  • EASL position paper on clinical follow-up after HCV cure [2024]
  • Policy statement on drug use and the global hepatitis C elimination goal [2020]
  • EASL recommendations on treatment of hepatitis C: Final update of the series [2020]
  • Eliminating Hepatitis C – an Action Plan [2019]
  • EASL Recommendations on Treatment of Hepatitis C 2018 [2018]
  • Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015 [2015]
  • EASL Clinical Practice Guidelines: Management of hepatitis C virus infection [2014]

• European Centre for Disease Prevention and Control
  • Guidelines on the prevention of hepatitis C virus transmission through substances of human origin [2026]
  • Hepatitis C

• European Society of Clinical Microbiology and Infectious Diseases
  • Elimination of hepatitis C in Europe: can WHO targets be achieved? [2020]

• Frontiers in Pharmacology
  • Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future [2016]

• Harm Reduction Journal
  • The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries [2020]
  • Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries [2019]

• International Journal of Environmental Research and Public Health
  • The Effectiveness and Cost-Effectiveness of Hepatitis C Screening for Migrants in the EU/EEA: A Systematic Review [2018]

• Liver International
  • The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries [2021]

• Pathogens
  • Hepatitis C Virus Infection in Europe [2024]

France

• BMC Infectious Diseases
  • French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long [2020]
  • Rapid and large-scale implementation of HCV treatment advances in France, 2007–2015 [2017]

• Clinics and Research in Hepatology and Gastroenterology
  • Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus [2022]

• Journal of Viral Hepatitis
  • Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO Study [2025]

• PLoS ONE
  • The Undiagnosed Chronically-Infected HCV Population in France. Implications for Expanded Testing Recommendations in 2014 [2015]

• Viruses
  • Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014-2021 [2024]

• World Journal of Hepatology
  • European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift [2018]

Georgia

• Centers for Disease Control and Prevention
  • Progress in Testing for and Treatment of Hepatitis C Virus Infection Among Persons Who Inject Drugs — Georgia, 2018 [2019]

• PLoS Medicine
  • Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020 [2023]

• Public Health
  • The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia [2022]

Germany

• BMC Infectious Diseases
  • Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies [2019]
  • Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany - an application of the efficiency frontier approach [2015]

• BMJ Open Gastroenterology
  • Economic study of the value of expanding HCV treatment capacity in Germany [2017]

• Institute for Quality and Efficiency in Health Care
  • Glecaprevir/pibrentasvir (chronic hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V [2019]
  • Elbasvir/grazoprevir (chronic hepatitis C) - Benefit assessment according to §35a Social Code Book V [2017]

• International Journal of Environmental Research and Public Health
  • Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany [2020]

• PLoS ONE
  • Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results [2020]
  • Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany [2017]
  • Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study [2016]

• Visceral Medicine
  • The New Era of Interferon-Free Treatment of Chronic Hepatitis C [2015]

Greece

• Annals of Gastroenterology
  • Aiming towards hepatitis C virus elimination in Greece [2019]

• World Journal of Gastroenterology
  • Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals [2019]

High-income countries

• BMC Primary Care
  • Prescribing direct-acting antivirals for hepatitis C treatment: a scoping review of factors that influence primary care providers [2025]

• Epidemiology & Infection
  • A scoping review on the community dividend resulting from testing and treating hepatitis C infection in people living in detention [2024]

• Journal of Viral Hepatitis
  • Synchronous Telemedicine Versus In-Person Care in Hepatitis C Treatment: A Systematic Review and Meta-Analysis [2026]

• World Journal of Hepatology
  • Comparison of hepatitis C virus testing recommendations in high-income countries [2018]

Hungary

• Viruses
  • Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents [2022]

Iceland

• Clinical Infectious Diseases
  • High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study [2022]

• International Journal of Drug Policy
  • Predictors of treatment outcomes for Hepatitis C infection in a nationwide elimination program in Iceland: The treatment as prevention for Hepatitis C (TraP HepC) study [2024]

India

• Indian Pediatrics
  • Management of Hepatitis C in Children - A New Paradigm [2023]

• Journal of Clinical and Experimental Hepatology
  • Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015 [2015]
  • Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India [2014]

International

• Annual Review of Medicine
  • Global Elimination of Hepatitis C Virus [2025]

• Autoimmune Diseases
  • International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement [2017]

• BioMed Research International
  • Performance of HCV Antigen Testing for the Diagnosis and Monitoring of Antiviral Treatment: A Systematic Review and Meta-Analysis [2022]

• BMC Infectious Diseases
  • Impact of the COVID-19 pandemic on hepatitis C care across the cascade of care: a scoping review [2026]
  • Risk of drug-induced liver injury in chronic hepatitis C and tuberculosis co- infection: a systematic review and meta- analysis [2025]

• BMC Public Health
  • A scoping review on HCV screening strategies: population to screen and the test types [2025]

• BMJ Open
  • Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations [2016]

• Ciência & Saúde Coletiva
  • Factors associated with hepatitis C treatment adherence: an integrative review [2022]

• Clinical Microbiology and Infection
  • Hepatitis C: global epidemiology and strategies for control [2016]

• Clinical Pharmacology & Therapeutics
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-a–Based Regimens [2014]

• EClinicalMedicine
  • Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis [2020]

• European Society for Paediatric Gastroenterology Hepatology and Nutrition
  • ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings [2024]

• EuroSurveillance
  • Towards eliminating hepatitis C as a public health threat: different speeds, different needs [2024]

• Gut and Liver
  • Precision Strategy for Hepatocellular Carcinoma Surveillance after Hepatitis C Cure: Debates across Guidelines [2025]

• Infectious Diseases of Poverty
  • Diagnostic performance of hepatitis C virus core antigen testing for detecting hepatitis C in people living with hepatitis B: a systematic review and meta-analysis [2024]

• International Federation of Kidney Foundations
  • Hepatitis C virus infection and global kidney health: the consensus proceedings of the International Federation of Kidney Foundations [2020]

• International Journal of Environmental Research and Public Health
  • Success Metrics for Hepatitis C Elimination Among People Who Inject Drugs: A Scoping Review of Indicators in Harm Reduction [2025]

• International Liver Transplantation Society
  • International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients [2017]
  • International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates [2017]

• International Network on Hepatitis in Substance Users
  • Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework [2019]
  • Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs [2017]
  • Recommendations for the management of hepatitis C virus infection among people who inject drugs [2015]

• JHEP Reports
  • Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines [2021]

• Journal of Clinical Pharmacy and Therapeutics
  • Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis [2022]

• Journal of Preventive Medicine and Public Health
  • Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination [2021]

• Journal of Virus Eradication
  • Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17–18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework [2018]

• KDIGO
  • Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update [2023]
  • KDIGO 2022 Clinical Practice Guideline FOR the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease [2022]
  • KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease [2018]
  • Hepatitis C in CKD

• Lancet Gastroenterology and Hepatology
  • A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles [2025]
  • Impact of hepatitis C virus point-of-care RNA viral load testing compared with laboratory-based testing on uptake of RNA testing and treatment, and turnaround times: a systematic review and meta-analysis [2023]

• Pathogens
  • Hepatitis C Virus-Pediatric and Adult Perspectives in the Current Decade [2024]

• PLoS Medicine
  • Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis [2016]

• Scientific Reports
  • Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data [2016]

• Viruses
  • Hepatitis C Virus: Epidemiological Challenges and Global Strategies for Elimination [2025]
  • Elimination of HCV Infection: Recent Epidemiological Findings, Barriers, and Strategies for the Coming Years [2024]

• World Journal of Gastroenterology
  • Cascade of care for children and adolescents with chronic hepatitis C [2021]

Iran

• Harm Reduction Journal
  • Engagement in hepatitis C virus cascade of care and factors associated with testing among people who inject drugs in Iran [2025]

Ireland

• Department of Health Ireland
  • Hepatitis C Screening [2020]

• Health Information and Quality Authority
  • HTA of birth cohort testing for hepatitis C [2024]
  • Another Step Toward Hepatitis C Elimination: An Economic Evaluation of an Irish National Birth Cohort Testing Program [2022]

Israel

• Advances in Therapy
  • Road to Hepatitis C Elimination in Israel: Improvements in Linkage to Care (2009-2020) [2025]

• Emerging Infectious Diseases
  • Economic Analysis of National Program for Hepatitis C Elimination, Israel, 2023 [2024]

• Harm Reduction Journal
  • Hepatitis C in Israeli prisons: status report [2020]

• Health Care Management Science
  • Country versus pharmaceutical company interests for hepatitis C treatment [2022]

Italy

• BMC Infectious Diseases
  • Meet-Test-Treat for HCV management: patients' and clinicians' preferences in hospital and drug addiction services in Italy [2022]
  • Proceedings of the Second Workshop of the Regional Study Group on HCV in the Calabria Region (Southern Italy). The virus-host-therapy pathway in HCV disease management: from bench to bedside in the era of Directly Actin [2012]

• ClinicoEconomics and Outcomes Research
  • Optimizing choice of oral interferon-free treatment for genotype 1 hepatitis C virus using testing for NS5A resistance: a cost-utility analysis from the perspective of the Italian National Health Service [2017]
  • Financial and feasibility implications of the treatment of hepatitis C virus in Italy: scenarios and perspectives [2016]

• Digestive and Liver Disease
  • Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation [2022]
  • Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF) [2013]

• International Journal of Environmental Research and Public Health
  • Drug–Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study [2021]

• Journal of Viral Hepatitis
  • Long-Term Effects of Direct-Acting Antivirals on Hepatitis C: Trends in Liver Disease-Related Hospitalisations in Italy [2025]

• Pathogens
  • Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study [2025]

Japan

• Asian Pacific Journal of Cancer Prevention
  • Quantifying the Contribution of Viral Hepatitis Control Policies and Improvement of Hepatitis C Treatment in Japan during 2000-2030 based on Simulation Modelling [2025]

• Drug Design, Development and Therapy
  • Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study [2016]

• Journal of Gastroenterology
  • Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines [2013]

• Scientific Reports
  • Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies [2023]

• Viruses
  • HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy [2015]

• World Journal of Gastroenterology
  • Liver biopsy in the post-hepatitis C virus era in Japan [2024]

• World Journal of Hepatology
  • Natural interferon-beta treatment for patients with chronic hepatitis C in Japan [2015]

Kuwait

• Hepatic Medicine : Evidence and Research
  • Expert opinion on the management of hepatitis C infection in Kuwait [2018]

• World Journal of Gastroenterology
  • Accelerating the elimination of hepatitis C in Kuwait: An expert opinion [2020]

Latin America

• World Journal of Gastroenterology
  • Need of righteous attitudes towards eradication of hepatitis C virus infection in Latin America [2016]

Low and middle income countries

• BMC Infectious Diseases
  • Economic evaluation of HCV testing approaches in low and middle income countries [2017]

• BMJ Global Health
  • Initial success from a public health approach to hepatitis C testing, treatment and cure in seven countries: the road to elimination [2020]

• Clinical Infectious Diseases
  • Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes From National Treatment Programs in Three Low- and Middle-Income Countries [2022]

• International Journal of Environmental Research and Public Health
  • Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis [2020]

• World Health Organization
  • Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries [2021]
  • Progress report on access to hepatitis C treatment: focus on overcoming barriers in low- and middle-income countries [2018]

Malaysia

• Ministry of Health Malaysia
  • Management of Chronic Hepatitis C in Adults [2019]

Maldives

• Ministry of Health Maldives
  • National Guideline for the Diagnosis and Management of Hepatitis C [2019]

Mexico

• Viruses
  • Hepatitis C Virus Resistance-Associated Substitutions in Mexico [2025]

Middle East, North Africa

• Hepatology Communications
  • Who to Test for Hepatitis C Virus in the Middle East and North Africa?: Pooled Analyses of 2,500 Prevalence Measures, Including 49 Million Tests [2019]

• Viruses
  • Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies [2021]

• World Journal of Gastroenterology
  • Systematic overview of hepatitis C infection in the Middle East and North Africa [2018]

Mongolia

• Viruses
  • Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia [2025]

Netherlands

• European Journal of Internal Medicine
  • Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination [2022]

• PLoS ONE
  • Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study [2016]

New Zealand

• Health New Zealand
  • National Hepatitis C Action Plan for Aotearoa New Zealand [2021]
  • Hepatitis C

Nordic countries

• PLoS ONE
  • Policy responses to hepatitis C in the Nordic countries: Gaps and discrepant reporting in the Hep-Nordic study [2018]

Norway

• BMJ Open
  • On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017 [2020]

• EuroSurveillance
  • Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: a registry-based study to monitor progress towards elimination [2024]

OECD countries

• Journal of Viral Hepatitis
  • Peer Interventions for Hepatitis C Testing and Treatment in OECD Countries: A Systematic Scoping Review [2026]

Pakistan

• Asian Pacific Journal of Tropical Medicine
  • Effect of interferon plus ribavirin therapy on hepatitis C virus genotype 3 patients from Pakistan: Treatment response, side effects and future prospective [2015]

• BMJ Open
  • Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections [2019]

• Frontiers in Public Health
  • Stakeholder perspectives and the challenges in implementing hepatitis C elimination policy in Pakistan [2025]

• Journal of Viral Hepatitis
  • A Health Systems Strengthening Approach to Address the High Burden of Hepatitis C in Pakistan [2025]

• Lancet Global Health
  • Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis [2020]

Philippines

• Hepatology Society of the Philippines
  • The 2018 Update to the Consensus Statements on the Diagnosis and Treatment of Hepatitis C [2018]

Poland

• BMJ Open
  • What affects response rates in primary healthcare-based programmes? An analysis of individual and unit-related factors associated with increased odds of non-response based on HCV screening in the general population in Poland [2016]

• Clinical and Experimental Hepatology
  • Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020 [2020]
  • Recommendations for the treatment of hepatitis C in 2017 [2017]
  • Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study [2016]

• Przeglad Epidemiologiczny - Epidemiological Review
  • Recommendations for the treatment of hepatitis C Polish group of HCV Experts--2015 [2015]
  • Standards of hepatitis C treatment. Recommendations of Polish Group of Experts--2014 [2014]

Portugal

• BMC Infectious Diseases
  • Consensus for the integrated management of hepatitis C in Portugal [2014]

Republic of Korea

• Clinical and Molecular Hepatology
  • Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness [2025]
  • Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL [2018]

• Journal of Infection and Public Health
  • Economic evaluation of mass screening as a strategy for hepatitis C virus elimination in South Korea [2025]

• Korean Association for the Study of the Liver
  • 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C [2018]
  • KASL clinical practice guidelines: management of hepatitis C [2016]

• Korean Journal of Internal Medicine
  • Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study [2023]

Russia

• PLoS ONE
  • Streamlining the screening cascade for active Hepatitis C in Russia: A cost-effectiveness analysis [2019]

Rwanda

• BMC Infectious Diseases
  • Risk factors for viral hepatitis C infection in Rwanda: results from a nationwide screening program [2019]

• Viruses
  • The Cascade of Care for Hepatitis C Treatment in Rwanda: A Retrospective Cohort Study of the 2017-2019 Mass Screening and Treatment Campaign [2023]

Saudi Arabia

• Saudi Journal of Gastroenterology
  • SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024 [2024]
  • Epidemiology, Disease Burden, and Treatment Strategies of Chronic Hepatitis C Virus Infections in Saudi Arabia in the New Treatment Paradigm Shift [2016]
  • SASLT Practice Guidelines: Management of Hepatitis C Virus Infection [2012]

Singapore

• Communicable Diseases Agency
  • Hepatitis C

• Journal of Gastroenterology and Hepatology
  • What is required for achieving HCV elimination in Singapore? A modeling study [2020]

• Singapore Medical Journal
  • Elimination of chronic viral hepatitis C in correctional health [2025]

Spain

• Frontiers in Public Health
  • Let's End HepC: Modelling Public Health Epidemiological Policies Applied to Hepatitis C in Spain [2022]

• Health Policy
  • The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain - Health Policy [2016]

• Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
  • Executive summary: Consensus document of GEHEP of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), along with SOCIDROGALCOHOL, SEPD and SOMAPA on hepatitis C virus infection management in drug users Infecciosas y Microbiología Clínica [2020]

Sub-Saharan Africa

• BMC Health Services Research
  • Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa [2022]

Sweden

• Infectious Diseases
  • Treatment uptake among individuals notified with HCV infection 1990-2022 in Sweden [2026]
  • Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations [2015]

• Liver International
  • Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19 [2021]

Switzerland

• PLoS ONE
  • Drug Pricing Evolution in Hepatitis C [2016]
  • Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations [2016]
  • Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C [2015]

• Swiss Medical Weekly
  • Real-life experience of chronic hepatitis C treatment in Switzerland: a retrospective analysis [2024]
  • Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort [2021]
  • Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions [2019]

Taiwan

• BMC Public Health
  • Gender differences in risk exposures for acute hepatitis C infection in Taiwan: a nationwide case-control study [2023]

• Hepatology International
  • An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan [2024]
  • Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry [2023]

• Journal of the Formosan Medical Association
  • Nationwide hepatitis C virus microelimination in uremic patients undergoing maintenance hemodialysis in Taiwan [2025]
  • Micro-elimination of hepatitis C in patients with chronic kidney disease and diabetes in Taiwan [2025]
  • Investing in health: Policy lessons from reimbursing direct-acting antivirals for hepatitis C in Taiwan [2025]
  • Hepatitis C virus microelimination among men who have sex with men in Taiwan: Our progress, achievements, and remaining challenges [2025]
  • Hepatitis C micro-elimination in people who inject drugs: Incarcerated or methadone maintenance therapy in Taiwan [2025]
  • HCV elimination in hyperendemic areas: Experiences in Taiwan [2025]
  • Current status of HCV elimination in Taiwan [2025]
  • Current status and unmet needs of pediatric HCV infection in Taiwan [2025]
  • TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes [2023]
  • Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan [2022]
  • 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population [2020]
  • 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations [2020]

• Kaohsiung Journal of Medical Sciences
  • Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide [2024]

• Medicine
  • Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C [2015]

Thailand

• BMC Gastroenterology
  • Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6 [2016]

• Bulletin of the World Health Organization
  • Community-based integrated care for HIV, viral hepatitis and sexually transmitted infections, Thailand [2026]

• PLoS ONE
  • Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era [2016]

Türkiye

• Balkan Medical Journal
  • Evaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective Study [2016]

• Turkish Journal of Gastroenterology
  • Modeling the Health Economic Burden of Hepatitis C Virus Infection in Turkey: Cost-Effectiveness of Targeted Screening [2023]
  • Efficacy and Safety of Direct-Acting Antivirals in Elderly Patients with Chronic Hepatitis C: A Nationwide Real-Life, Observational, Multicenter Study from Turkey [2022]
  • Turkey 2017 Clinical Practice Guidelines on recommendations for screening diagnosing and managing hepatitis C virus [2017]
  • Recommendation for treatment of hepatitis C virus infection [2017]

United Kingdom

• Alimentary Pharmacology & Therapeutics
  • 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy [2014]

• British Journal of General Practice
  • Hepatitis C diagnosis and management: a primary care and public health partnership approach [2022]
  • Eliminating hepatitis C: time to embrace primary care's critical role? [2021]

• Clinical Infectious Diseases
  • The Effectiveness of Low Dead Space Syringes for Reducing the Risk of Hepatitis C Virus Acquisition Among People Who Inject Drugs: Findings From a National Survey in England, Wales, and Northern Ireland [2022]

• EuroSurveillance
  • Monitoring liver transplant rates in persons diagnosed with hepatitis C: a data linkage study, England 2008 to 2017 [2019]
  • A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs [2018]

• Health Technology Assessment
  • The impact and cost-effectiveness of scaling up HCV treatment for achieving elimination among people who inject drugs in England: a synopsis including evidence synthesis and economic modelling [2026]

• International Journal of Drug Policy
  • Can real-world scaling up HCV treatment in people who inject drugs be cost-saving: an economic modelling study in the UK [2026]
  • Using modelling and public health surveillance data to evidence progress towards the WHO incidence target for hepatitis C elimination in people who inject drugs - a review of complementary approaches in the United Kingdom [2025]

• Journal of Infection
  • Direct-acting antiviral treatment outcomes in people infected with endemic compared to epidemic hepatitis C virus subtypes in England [2025]

• Journal of Viral Hepatitis
  • Assessing uncertainty in the burden of hepatitis C virus: Comparison of estimated disease burden and treatment costs in the UK [2018]

• Medicines and Healthcare products Regulatory Agency
  • Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR [2017]
  • Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation [2017]

• National Institute for Health and Care Excellence
  • Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C [2018]
  • Glecaprevir–pibrentasvir for treating chronic hepatitis C [2018]
  • Sofosbuvir–velpatasvir for treating chronic hepatitis C [2017]
  • Elbasvir–grazoprevir for treating chronic hepatitis C [2016]
  • Sofosbuvir for treating chronic hepatitis C [2015]
  • Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C [2015]
  • Ledipasvir–sofosbuvir for treating chronic hepatitis C [2015]
  • Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people [2013]
  • Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C [2010]

• NHS England
  • Hepatitis C Care Clinical Network Specification [2023]
  • Antivirals for adults with recent onset (acute) hepatitis C [2019]
  • Treatment of chronic Hepatitis C in patients with cirrhosis [2015]

• PLoS ONE
  • Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections [2015]

• Public Health England
  • Screening for hepatitis C infection [2017]
  • Hepatitis C: interventions for case-finding and linkage to care

• Public Health Scotland
  • Hepatitis C

• UK Health Security Agency
  • Hepatitis C: migrant health guide
  • Hepatitis C: guidance, data and analysis

United States

• Adolescent Health, Medicine and Therapeutics
  • Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges [2021]

• Agency for Healthcare Research and Quality
  • Screening for Hepatitis C Virus Infection in Adolescents and Adults: A Systematic Review Update for the U.S. Preventive Services Task Force [2020]
  • Screening for Hepatitis C Virus Infection in Adults - Comparative Effectiveness Review Summary Guides for Clinicians [2013]
  • Treatment for Hepatitis C Virus Infection in Adults [2012]
  • Comparative Effectiveness of Treatments for Chronic Hepatitis C Virus Infection in Adults [2012]

• American Association for the Study of Liver Diseases
  • The national hepatitis C elimination program-AASLD's coalition and call to action [2023]
  • Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [2023]
  • Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [2020]
  • Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection [2018]
  • An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases [2011]
  • Testing, Evaluation, and Monitoring of Hepatitis C
  • Retreatment of Persons in Whom Prior Therapy Failed
  • Recommendations for Testing, Managing, and Treating Hepatitis C
  • Initial Treatment of HCV Infection
  • Hepatitis C

• American College of Physicians
  • World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians [2021]

• American Gastroenterological Association
  • AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review [2020]
  • American Gastroenterological Association Institute Clinical Practice Update—Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection [2017]

• American Journal of Epidemiology
  • Hepatitis C virus transmission among people who inject drugs in rural United States: mathematical modeling study using stochastic agent-based network simulation [2026]

• American Journal of Managed Care
  • Value of Expanding HCV Screening and Treatment Policies in the United States [2016]
  • Costs and Spillover Effects of Private Insurers’ Coverage of Hepatitis C Treatment [2016]
  • Accessing the Cure: Helping Patients With Hepatitis C Overcome Barriers to Care [2016]

• American Journal of Medicine
  • Hepatitis C Management at Federally Qualified Health Centers during the Opioid Epidemic: A Cost-Effectiveness Study [2020]

• American Journal of Preventive Medicine
  • Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic [2021]

• American Journal of Public Health
  • Comparison of Current US Risk Strategy to Screen for Hepatitis C Virus With a Hypothetical Targeted Birth Cohort Strategy [2012]

• American Society of Transplantation
  • The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation [2017]

• BMC Gastroenterology
  • Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US [2015]

• Cancer Medicine
  • Less Restrictive Medicaid Policies for Direct-Acting Antiviral Access Are Associated With Greater Declines in Hepatocellular Carcinoma Deaths [2026]

• Centers for Disease Control and Prevention
  • State-Specific Hepatitis C Virus Clearance Cascades — United States, 2013–2022 [2024]
  • Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States [2024]
  • Updated Operational Guidance for Implementing CDC’s Recommendations on Testing for Hepatitis C Virus Infection [2023]
  • Hepatitis C Virus Clearance Cascade — United States, 2013–2022 [2023]
  • Vital Signs: Hepatitis C Treatment Among Insured Adults — United States, 2019–2020 [2022]
  • Hepatitis C Virus (HCV) Infection - STI Treatment Guidelines [2021]
  • Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus — CDC Guidance, United States, 2020 [2020]
  • CDC Recommendations for Hepatitis C Screening Among Adults — United States, 2020 [2020]
  • Too Few People Treated for Hepatitis C
  • Hepatitis C
  • Clinical Screening and Diagnosis for Hepatitis C
  • Clinical Care of Hepatitis C

• Clinical Infectious Diseases
  • State-of-the-Art Review: Hepatitis C [2025]
  • The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination [2024]

• Current Gastroenterology Reports
  • Update on Pediatric Hepatitis C Infection [2025]

• Endocrine Practice
  • Clinical Monitoring of Chronic Hepatitis C Based on its Natural History and Therapy [2013]

• Expert Review of Pharmacoeconomics & Outcomes Research
  • Cost effectiveness of hepatitis C direct acting agents [2024]

• Family Medicine
  • Hepatitis C Treatment by Early-Career US Family Physicians [2026]

• Federal Bureau of Prisons
  • Evaluation and Management of Chronic Hepatitis C Virus Infection [2021]

• Hepatic Medicine : Evidence and Research
  • Ending hepatitis C in the United States: the role of screening [2014]

• Hepatitis C Online
  • Treatment of Key Populations and Unique Situations
  • Treatment of Hepatitis C Infection
  • Screening and Diagnosis of Hepatitis C Infection
  • Medications to Treat HCV
  • Management of Cirrhosis-Related Complications
  • Hepatitis C Online
  • Evaluation, Staging, and Monitoring of Chronic Hepatitis C
  • Evaluation and Preparation for Hepatitis C Treatment

• Infectious Agents and Cancer
  • Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States [2016]

• Infectious Diseases and Therapy
  • Desirable Characteristics of Hepatitis C Treatment Regimens: A Review of What We Have and What We Need [2016]

• JAMA Health Forum
  • Health and Economic Impact of Periodic Hepatitis C Virus Testing Among People Who Inject Drugs [2025]

• JAMA Internal Medicine
  • Health Benefits, Costs, and Cost-Effectiveness of Jail-Based Hepatitis C Elimination Strategies [2026]

• JAMA Network Open
  • Cost-Effectiveness of Point-of-Care Hepatitis C Virus RNA Testing in the US [2026]
  • Medicaid Expansion and Restriction Policies for Hepatitis C Treatment [2024]
  • Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States [2020]

• Journal of Clinical and Translational Hepatology
  • Assessing the Effectiveness of Strategies in US Birth Cohort Screening for Hepatitis C Infection [2020]

• Journal of Managed Care & Specialty Pharmacy
  • The association of direct-acting antiviral therapy with health care utilization and costs in patients with chronic hepatitis C virus infection: A systematic review of real-world studies in the United States [2025]
  • Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective [2022]

• Journal of Viral Hepatitis
  • A Framework for Emergency Department-Integrated Hepatitis C Test-and-Treat in the United States [2026]

• Liver International
  • HCV Council – critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape [2015]

• New York State Department of Health AIDS Institute
  • Treatment of Chronic Hepatitis C Virus Infection in Adults
  • Pretreatment Assessment in Adults With Chronic Hepatitis C Virus Infection
  • Hepatitis C Virus Screening, Testing, and Diagnosis in Adults

• Open Forum Infectious Diseases
  • The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets [2018]

• Pathogens
  • Updated Clinical Guidelines on the Management of Hepatitis C Infection in Children [2024]

• Pediatrics
  • Disparities in Linkage to Care Among Children With Hepatitis C Virus in the United States [2025]

• PLoS ONE
  • Disparities in the quality of care for chronic hepatitis C among Medicare beneficiaries [2022]

• Seminars in Dialysis
  • Hepatitis C Virus Screening and Management of Seroconversions in Hemodialysis Facilities [2013]

• U.S. Preventive Services Task Force
  • Hepatitis C Virus Infection in Adolescents and Adults: Screening [2020]

• Vaccine
  • Challenges in coverage of future hepatitis C vaccines: Review and potential solutions [2025]

• Viruses
  • Potential Cost-Effectiveness of Machine Learning-Enabled Primary Care Identification of Hepatitis C Virus Patients in the US [2026]

Western countries

• BMC Public Health
  • Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence [2023]

• International Journal of Drug Policy
  • Interventions to increase linkage to care and adherence to treatment for hepatitis C among people who inject drugs: A systematic review and practical considerations from an expert panel consultation [2022]

• Substance Abuse Treatment, Prevention, and Policy
  • Future destinations and social inclusion scoping review: how people cured of hepatitis C (HCV) using direct- acting antiviral drugs progress in a new HCV-free world [2022]

WHO

• World Health Organization
  • New recommendation on hepatitis C virus testing and treatment for people at ongoing risk of infection: policy brief [2023]
  • Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and diagnostics [2022]
  • Updated recommendations on treatment of adolescents and children with chronic HCV infection [2022]
  • Updated recommendations on simplified service delivery and diagnostics for hepatitis C infection [2022]
  • Recommendations and guidance on hepatitis C virus self-testing [2021]
  • Access to hepatitis C testing and treatment for people who inject drugs and people in prisons — a global perspective [2019]
  • Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection [2018]
  • Collaborative study to evaluate the proposed 4th WHO international standards for Hepatitis C Virus (HCV) for Nucleic Acid Amplification Technology (NAT)-Based Assays [2011]
  • Hepatitis C: Fact sheet

Zimbabwe

• International Journal of Environmental Research and Public Health
  • Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe [2025]

{Related topics}

• Topic
  • Hepatitis in pregnancy and newborn
  • Hepatitis C: epidemiology
  • Hepatitis
  • HIV/AIDS and hepatitis